Summary by Futu AI
On January 29, 2024, 60 Degrees Pharmaceuticals, Inc., a Delaware-based company, entered into an Underwriting Agreement with WallachBeth Capital LLC for a public offering of 5,260,901 units at $0.385 per unit and 999,076 pre-funded units at $0.375 per pre-funded unit. The offering included common stock and warrants, with the warrants exercisable immediately and expiring five years from the date of issuance. The underwriters were granted an over-allotment option, which was partially exercised on January 31, 2024, for additional warrants. The offering closed on January 31, 2024, with net proceeds of approximately $1.9 million after underwriting discounts, commissions, and offering expenses. The proceeds are intended for capitalization, financial flexibility, and the relaunch of the company's malaria prevention project in the U.S. Company officers and directors have agreed not to sell or dispose of any common stock until July 29, 2024, without WallachBeth Capital LLC's consent. The offering was made under the company's Registration Statement on Form S-1, declared effective by the SEC on January 29, 2024.